Kira Gordon and Matt Majewski recently authored an article in MedTech Strategist discussing how hospital consolidation is increasing purchasing leverage through greater pricing transparency and that has substantiated a need for new pricing models in medtech. There are challenges associated with several emerging pricing models; regardless, manufacturers will need to develop innovative approaches to maximize opportunity while minimizing risk.
Drug price controls in the US: A roundtable discussion with experts
The United States is the world leader in innovative drug development, supporting patients and health systems globally by advancing the creation of new cures...